阿得贝利单抗联合贝伐珠单抗及铂类治疗三阴性乳腺癌脑转移的II期研究
该II期研究纳入35例活动性脑转移的三阴性乳腺癌患者,接受阿得贝利单抗、贝伐珠单抗联合顺铂/卡铂治疗。确认的CNS-ORR为77.1%,CNS-CBR为80.0%,中位PFS 8.3个月,中位CNS-PFS 10.3个月,中位OS 21.1个月。≥3级治疗相关不良事件发生率为65.7%,安全性可控。
要点
- 三药联合在TNBC脑转移中显示高颅内缓解率(CNS-ORR 77.1%)
- 中位CNS-PFS达10.3个月,中位OS达21.1个月
- ≥3级治疗相关不良事件发生率65.7%,需关注安全性管理
核心结论
- 阿得贝利单抗联合贝伐珠单抗及顺铂/卡铂是首个在TNBC脑转移中显示有前景的颅内抗肿瘤活性并延长PFS和CNS-PFS的方案,安全性可控,值得进一步研究。
研究设计与样本
- II期临床试验,纳入35例活动性脑转移的三阴性乳腺癌患者。
- 患者接受阿得贝利单抗、贝伐珠单抗联合顺铂/卡铂治疗,直至疾病进展或不可接受的毒性。
- 主要终点为基于RANO-BM标准的CNS客观缓解率(CNS-ORR),次要终点包括CNS临床获益率(CNS-CBR)、PFS、OS、首次进展部位和安全性。
主要发现
- 确认的CNS-ORR为77.1%(27/35,95% CI 59.9-89.6),CNS-CBR为80.0%(28/35,95% CI 63.1-91.6)。
- 中位总体PFS为8.3个月(95% CI 5.8-11.5),中位CNS-PFS为10.3个月(95% CI 7.4-14.3),中位OS为21.1个月(95% CI 13.2-未达到)。
- 在28例进展患者中,仅颅内进展占32.1%(9/28),仅颅外进展占35.7%(10/28),颅内和颅外同时进展占32.1%(9/28)。
- ≥3级治疗相关不良事件发生率为65.7%(23/35),治疗相关严重不良事件发生于5例患者(14.3%),未报告治疗相关死亡。
临床怎么用
- 该三药联合方案在TNBC活动性脑转移患者中显示出较高的颅内缓解率和可管理的安全性,可考虑作为潜在治疗选择,但需进一步验证。
局限性
- 本研究为单臂II期临床试验,样本量有限(35例),缺乏随机对照,结论需在更大规模研究中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Brain metastases (BMs) of triple-negative breast cancer (TNBC) are lethal, often associated with a limited life span and lack of effective antitumor agents. Here we reported a triple combination therapy consisting of adebrelimab, bevacizumab, and cisplatin/carboplatin in BMs of TNBC. METHODS: This phase II clinical trial involved patients with TNBC with active BMs. Participants were administered with adebrelimab, bevacizumab, and cisplatin/carboplatin until disease progression or unacceptable toxic effects. The primary end point was the objective response rate in CNS (CNS-ORR) according to the Response Assessment in Neuro-Oncology BMs criteria, and the secondary end points included the clinical benefit rate in CNS (CNS-CBR), progression-free survival (PFS), overall survival (OS), the first progression site, and safety. RESULTS: A total of 35 patients were enrolled and treated, and the median lines of previous treatment were 2 (range, 0-4). The confirmed CNS-ORR was 77.1% (27/35, 95% CI, 59.9 to 89.6), and the CNS-CBR was 80.0% (28/35, 95% CI, 63.1 to 91.6). The median overall PFS was 8.3 months (95% CI, 5.8 to 11.5), whereas the median CNS-PFS was 10.3 months (95% CI, 7.4 to 14.3) and the median OS was 21.1 months (95% CI, 13.2 to not reached). Among the 28 patients who progressed, progression was intracranial-only in 32.1% (9/28) patients, extracranial-only in 35.7% (10/28) patients, and both in 32.1% (9/28) patients. The incidence of grade ≥3 treatment-related adverse events was 65.7% (23/35). Treatment-related serious adverse events occurred in five patients (14.3%), and no treatment-related deaths were reported. CONCLUSION: The combination of adebrelimab, bevacizumab, and cisplatin/carboplatin was the first regimen to demonstrate promising intracranial antitumor activity and prolonged PFS and CNS-PFS, along with a manageable safety profile, warranting further investigation.
引用
- Li T, Zhou T, Wang B, et al. Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study). J Clin Oncol. 2026. PMID: 41779972. doi:10.1200/JCO-25-02021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。